All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Which factors help guide therapy choice for R/R diffuse large B-cell lymphoma?
Featured:
Gilles SallesDuring the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Which factors help guide therapy choice for relapsed/refractory (R/R) diffuse large B-cell lymphoma?
Which factors help guide therapy choice for R/R diffuse large B-cell lymphoma?
In this video, Salles discusses insights presented during EHA2021 regarding the selection of patients with R/R diffuse large B-cell lymphoma for second-line therapy. Although autologous hematopoietic stem cell transplant (auto-HSCT) remains the standard of care, a recent randomized study is comparing auto-HSCT with chimeric antigen receptor (CAR) T-cell therapy. Salles also points out that the antibody-drug conjugate loncastuximab tesirine could be a feasible approach prior to treatment with CAR T-cell therapy.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?